


CLAIMS

1. A bicycloamide derivative represented by the following general formula (1):



5 [wherein R^1 and R^2 may or may not be identical to one another and are each independently a hydrogen atom, substituted or unsubstituted C_1 to C_6 alkyl group, substituted or unsubstituted C_3 to C_6 cycloalkyl group, substituted or unsubstituted arylmethyl group, substituted or unsubstituted

10 arylethyl group, substituted or unsubstituted aromatic hydrocarbon group, substituted or unsubstituted aromatic heterocyclic ring, substituted or unsubstituted aliphatic heterocyclic ring or NR^3R^4 (wherein R^3 and R^4 may or may not be identical to one another and are each independently a hydrogen

15 atom, substituted or unsubstituted C_1 to C_6 alkyl group, substituted or unsubstituted C_3 to C_6 cycloalkyl group, substituted or unsubstituted arylmethyl group, substituted or unsubstituted aromatic hydrocarbon group, substituted or unsubstituted aromatic heterocyclic ring or substituted or


20 unsubstituted aliphatic heterocyclic ring, or R^3 and R^4 may together form a ring structure.), or R^1 and R^2 may together form a ring structure; X is CH_2 , CHF, CF_2 , CHOH, S or O; and n

is 1, 2 or 3.],

or a pharmaceutically acceptable salt thereof.

2. The bicycloamide derivative according to claim 1,


5 represented by the following general formula (2):



[wherein R⁵ is a substituted or unsubstituted C₁ to C₆ alkyl group, substituted or unsubstituted C₃ to C₆ cycloalkyl group, substituted or unsubstituted arylmethyl group, substituted or unsubstituted arylethyl group, substituted or unsubstituted aromatic hydrocarbon group, substituted or unsubstituted aromatic heterocyclic ring, substituted or unsubstituted aliphatic heterocyclic ring or NR³R⁴ (wherein R³ and R⁴ may or may not be identical to one another and are each independently a hydrogen atom, substituted or unsubstituted C₁ to C₆ alkyl group, substituted or unsubstituted C₃ to C₆ cycloalkyl group, substituted or unsubstituted arylmethyl group, substituted or unsubstituted aromatic hydrocarbon group, substituted or unsubstituted aromatic heterocyclic ring or substituted or unsubstituted aliphatic heterocyclic ring, or R³ and R⁴ may together form a ring structure.); X is CH₂, CHF, CF₂, CHOH, S or O; and n is 1, 2 or 3.],

or a pharmaceutically acceptable salt thereof.

3. The bicycloamide derivative according to claim 1, represented by the following general formula (3):




[wherein R^7 and R^8 may or may not be identical to one another and are each independently a substituted or unsubstituted C_1 to C_6 alkyl group, substituted or unsubstituted C_3 to C_6 cycloalkyl group, substituted or unsubstituted arylmethyl group, substituted or unsubstituted arylethyl group, substituted or unsubstituted aromatic hydrocarbon group, substituted or unsubstituted aromatic heterocyclic ring, substituted or unsubstituted aliphatic heterocyclic ring or NR^3R^4 (wherein R^3 and R^4 may or may not be identical to one another and are each independently a hydrogen atom, substituted or unsubstituted C_1 to C_6 alkyl group, substituted or unsubstituted C_3 to C_6 cycloalkyl group, substituted or unsubstituted arylmethyl group, substituted or unsubstituted aromatic hydrocarbon group, substituted or unsubstituted aromatic heterocyclic ring or substituted or unsubstituted aliphatic heterocyclic ring, or R^3 and R^4 may together form a ring structure.), or R^7 and R^8 may together form a ring

structure; X is CH₂, CHF, CF₂, CHOH, S or O; and n is 1, 2 or 3.],

or a pharmaceutically acceptable salt thereof.

4. An intermediate in the production of the bicycloamide derivative of claim 1, represented by the following formula (4):



[wherein R¹ and R² may or may not be identical to one another

and are each independently a hydrogen atom, substituted or

unsubstituted C₁ to C₆ alkyl group, substituted or

unsubstituted C₃ to C₆ cycloalkyl group, substituted or

unsubstituted arylmethyl group, substituted or unsubstituted

arylethyl group, substituted or unsubstituted aromatic

hydrocarbon group, substituted or unsubstituted aromatic

heterocyclic ring, substituted or unsubstituted aliphatic

heterocyclic ring or NR⁴R⁵ (wherein R⁴ and R⁵ may or may not be

identical to one another and are each independently a hydrogen

atom, substituted or unsubstituted C₁ to C₆ alkyl group,

substituted or unsubstituted C₃ to C₆ cycloalkyl group,

substituted or unsubstituted arylmethyl group, substituted or

unsubstituted aromatic hydrocarbon group, substituted or

unsubstituted aromatic heterocyclic ring or substituted or unsubstituted aliphatic heterocyclic ring, or R⁴ and R⁵ may together form a ring structure.), or R¹ and R² may together form a ring structure; X is CH₂, CHF, CF₂, CHOH, S or O; n is 1,
5 2 or 3; and P¹ is an amino-protecting group].

5. A pharmaceutical product, containing as an active ingredient the bicycloamide derivative according to claim 1 or a pharmaceutically acceptable salt thereof.

10

6. A DPP-IV inhibitor, containing as an active ingredient the bicycloamide derivative according to claim 1 or a pharmaceutically acceptable salt thereof.

15 7. A therapeutic agent for treating diseases involving DPP-IV, containing as an active ingredient the bicycloamide derivative according to claim 1 or a pharmaceutically acceptable salt thereof.

20 8. The therapeutic agent according to claim 7, wherein the disease involving DPP-IV is diabetes or a complication thereof.